Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
06/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
06/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
06/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
06/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
06/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
03/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
03/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
03/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
03/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 | ||
03/04/24 | 4 | Statement of changes in beneficial ownership of securities | 1 |